Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 1:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 110 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.5 mg Ranibizumab Clear all
Terminated Phase 3 Interventional Results available

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

NCT01940900
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
E10030, ranibizumab, E10030 sham intravitreal injection
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
49
States / cities
Tucson, Arizona • Fresno, California • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 5, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Results available

A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)

NCT02698566
View directory record Official record
Conditions
Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Paducah, Kentucky • Charlotte, North Carolina • Chattanooga, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 5, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Results available

Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema

NCT00444600
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Triamcinolone Acetonide + laser, Ranibizumab + laser, Sham injection + laser, Ranibizumab + deferred laser
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
50
States / cities
Artesia, California • Beverly Hills, California • Irvine, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 5, 2026, 1:45 AM EDT
Recruiting Phase 4 Interventional

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

NCT04853251
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
PDS Implant With Ranibizumab 100 mg/ml, LUCENTIS (Ranibizumab Injection)
Device · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
52
States / cities
Mesa, Arizona • Bakersfield, California • Huntington Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 5, 2026, 1:45 AM EDT
Completed Phase 1 Interventional

ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration

NCT00709527
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Avacincaptad Pegol
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 5, 2026, 1:45 AM EDT
Completed Phase 2 Interventional

Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).

NCT00713518
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
0.5 mg ranibizumab, 3 mg PF-04523655, 1 mg PF-04523655
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
San Francisco, California • Fort Myers, Florida • Winter Haven, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 5, 2026, 1:45 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)

NCT01225146
View directory record Official record
Conditions
Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases, Eye Diseases
Interventions
ranibizumab
Drug
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 5, 2026, 1:45 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)

NCT01115556
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Other
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 5, 2026, 1:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab

NCT02859441
View directory record Official record
Conditions
Von Hippel-Lindau Syndrome
Interventions
Ranibizumab, E10030
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 5, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration

NCT02510794
View directory record Official record
Conditions
Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Encino, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 5, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

NCT04690556
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
LUBT010 (proposed ranibizumab biosimilar), Lucentis (ranibizumab)
Drug
Lead sponsor
Lupin Ltd.
Industry
Eligibility
50 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
6
States / cities
Beverly Hills, California • Delray Beach, Florida • Hagerstown, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 5, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

Ranibizumab and Reduced Fluence PDT for AMD

NCT00527475
View directory record Official record
Conditions
Macular Degeneration
Interventions
ranibizumab, verteporfin
Drug
Lead sponsor
Texas Retina Associates
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Santa Barbara, California • Ann Arbor, Michigan • Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 5, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

NCT03362190
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Avacincaptad Pegol, Lucentis
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 5, 2026, 1:45 AM EDT
Completed Phase 2 Interventional

Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema

NCT00387582
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Ranibizumab (Lucentis), Argon Laser
Drug · Procedure
Lead sponsor
Rocky Mountain Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 5, 2026, 1:45 AM EDT
Withdrawn Phase 2 Interventional

Ranibizumab as a Rescue Therapy for Diabetic Macular Edema

NCT01253694
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
injection of 0.5 mg of Intravitreal Ranibizumab
Drug
Lead sponsor
New England Retina Associates
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Norwich, Connecticut
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 5, 2026, 1:45 AM EDT
Terminated Phase 2 Interventional Results available

The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration

NCT00857259
View directory record Official record
Conditions
Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration
Interventions
Everolimus, Ranibizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
4
States / cities
Beverly Hills, California • Sacramento, California • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 5, 2026, 1:45 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy

NCT00837330
View directory record Official record
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
ranibizumab 0.5 or 0.3 mg/0.05 cc
Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
35 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 5, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

Ranibizumab and Bevacizumab for Diabetic Macular Edema

NCT01610557
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab, Bevacizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 5, 2026, 1:45 AM EDT
Not listed Phase 2 Interventional

Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis

NCT00546936
View directory record Official record
Conditions
Presumed Ocular Histoplasmosis (POHS)
Interventions
ranibizumab, verteporfin
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Indianapolis, Indiana • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 16, 2009 · Synced Oct 5, 2026, 1:45 AM EDT
Withdrawn Phase 4 Interventional

Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy

NCT04075136
View directory record Official record
Conditions
Exudative Age Related Macular Degeneration
Interventions
Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide, verteporfin
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 5, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Results available

Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab

NCT01748292
View directory record Official record
Conditions
Macular Degeneration
Interventions
0.5 mg ranibizumab
Drug
Lead sponsor
Charles C Wykoff, PhD, MD
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
West Columbia, South Carolina • Houston, Texas • Katy, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 5, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)

NCT00931489
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab (Lucentis(R))
Drug
Lead sponsor
Lawrence S. Morse, MD
Other
Eligibility
50 Years and older
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 5, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration

NCT00304954
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
Intravenous Daclizumab, Intravenous Infliximab, Observation, Oral Rapamycin
Drug · Other
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 92 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 5, 2026, 1:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of Dosing Interval of Higher Doses of Ranibizumab

NCT00533520
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
ranibizumab
Drug
Lead sponsor
Brandon G. Busbee, MD
Other
Eligibility
50 Years to 95 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 5, 2026, 1:45 AM EDT